The randomized, placebo-controlled, triple-blind study was published inCurrent Nutraceuticals Journal.It was performed on 95 healthy adults.
The study demonstrated that Farlong NotoGinseng supplementation improved blood pressure, significantly lowered serum LDL cholesterol, and slightly raised serum HDL cholesterol. 17.5% of those in the treatment group saw improvement in all three CVD risk factors, compared to 5% of those on placebo, by week 12. It was well-tolerated.
Related: COVID-19 Underscores Importance of Heart Health Ingredients By Nature Acquires Citrus-Derived Heart Health Ingredient Farlong Donating Portion of Sales to Alzheimer’s Foundation of America
The study will be presented at the American Heart Association’s annual Scientific Sessions 2021, taking place November 13-15, with a global audience from over 100 countries. The study’s abstract will also be published inCirculation.
